Arcutis Biotherapeutics (NASDAQ: ARQT) revenue
Arcutis Biotherapeutics reported revenue of $376.1m for fiscal 2025, 91.3% more than in fiscal 2024 ($196.5m).
Arcutis Biotherapeutics has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $376.1m | +91.3% | −$12.2m | −3.3% |
| 2024 | $196.5m | +229.7% | −$128.4m | −65.3% |
| 2023 | $59.6m | +1,517.1% | −$241.1m | −404.5% |
| 2022 | $3.7m | — | −$301.6m | −8,183.0% |
| 2021 | $0.0m | — | −$206.5m | — |
| 2020 | $0.0m | — | −$136.6m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcutis Biotherapeutics revenue compared with its sector
By revenue for its latest fiscal year, Arcutis Biotherapeutics ranks 210th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arcutis Biotherapeutics, 91.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 208th | CareDx | $379.8m | 13.8% |
| 209th | Twist Bioscience | $376.6m | 20.3% |
| 210th | Arcutis Biotherapeutics | $376.1m | 91.3% |
| 211th | MannKind | $349.0m | 22.2% |
| 212th | Inogen | $348.7m | 3.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Arcutis Biotherapeutics
- How much revenue did Arcutis Biotherapeutics make in fiscal 2025?
- Arcutis Biotherapeutics reported revenue of $376.1m for fiscal 2025, compared with $196.5m in fiscal 2024.
- What was the best year for revenue at Arcutis Biotherapeutics?
- Of its last 6 fiscal years, fiscal 2025, with $376.1m.
- Where does Arcutis Biotherapeutics rank in its sector by revenue?
- It ranks 210th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Arcutis Biotherapeutics come from?
- From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Arcutis Biotherapeutics: the Arcutis Biotherapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.